|
|
|
|
Science Sparks @ ACTREC
|
 17th March 2025 |
Vol. No. 14 ; Issue No.674 |
|
|
Publications
|
|
1. Shroff K, Shetty P, Singh V, Epari S, Sahay A, Moiyadi A (2025). Clinical value of optimizing extent of resection in adult diffuse gliomas. Clinical Neurology and Neurosurgery. 251:108838.
2. Oak S, Karajgikar O, Gadewal N, Sulkshane P, Verma T, Gupta S, Teni T (2025). The deubiquitinase inhibitor WP1130 drives nuclear aggregation and reactivation of mutant p53 for selective cancer cell targeting. FEBS Journal.
3. Rajendra A, Sengar M, Korula A, Ganesan P, Jain H, K D, Samuel P, Perumal Kalaiyarasi J, Prakash G, John MJ, Palassery R, Nair CK, Shet T, Selvarajan S, Nayak L, Karunakaran P, Fouzia NA, Prakash O, Bagal B, Mehra N, Kumaran S, Epari S, Thorat J, Radhakrishnan V, Abraham A (2025). Outcomes and prognostic factors in patients with Burkitt lymphoma/leukemia in adolescents and adults: an experience from hematology cancer consortium. Blood Cancer Journal. 15(1):38.
4. Maitre P, Zaorsky N, Dess R, Koontz B, Tree A, Zilli T (2025). Precision over tradition: Transforming prostate cancer treatment with stereotactic radiation therapy. International Journal of Radiation Oncology,Biology Physics. 121(5): 1093-1097.
5. Hait S, Noronha V, Chowdhury A, Chaudhary A, Bawaskar B, Dahimbekar G, Ahmad S, Joshi A, Patil V, Menon N, Shah M, Kaushal R, Choughule A, Bharde A, Khandare J, Shafi G, Lakhwani D, Desai S, Chandrani P, Prabhash K, Dutt A (2025). The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer. ESMO Open, 10(4):104479.
|
|
|
|
|
Interesting Reads
|
|
Xiong A, Wang L, Chen J, Wu L, Liu B, Yao J, Zhong H, Li J, Cheng Y, Sun Y, Ge H, Yao J, Shi Q, Zhou M, Chen B, Han Z, Wang J, Bu Q, Zhao Y, Chen J, Nie L, Li G, Li X, Yu X, Ji Y, Sun D, Ai X, Chu Q, Lin Y, Hao J, Huang D, Zhou C, Shan J, Yang H, Liu X, Wang J, Shang Y, Mei X, Yang J, Lu D, Hu M, Wang ZM, Li B, Xia M, Zhou C (2025). Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet. 405(10481):839-849.
|
|
|
Video of the Week
|
|
| Oral Potentially Malignanat Lesions |
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 1975, Georges Kohler and Cesar Milstein developed the technique (hybridoma technology) for producing monoclonal antibodies against defined proteins.
|
|
|
|
Cancer News
|
| |
|
New test helps doctors predict a dangerous side effect of cancer treatment.
|
|
MedicalXpress, 10/03/2025
|
|
In this study, the research team analyzed the proteins in leftover cerebrospinal fluid taken from 29 patients with B-cell non-Hodgkin's lymphoma before they received CAR T therapy. Within that cohort, 11 patients developed ICANS while 18 patients did no...
|
| |
|
Environmental factors and genes play key role in cancer development
|
|
News-Medical, 11/03/2025
|
|
Infections also play a critical role in cancer risk. The Helicobacter pylori bacterium can cause stomach cancer by damaging stomach cells, while human papillomavirus (HPV) is strongly linked to cervical cancer. Other bacteria, viruses, and fungi can introduce genetic instability that contributes to...
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
2025 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
